TC BioPharm Inks LOI To Acquire Privately-held CAR-T Therapy Innovator
(RTTNews) - Biotechnology company TC BioPharm (Holdings) plc (TCBP) announced Monday the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors.
This agreement is the second such agreement in as many months that shows TC BioPharm's commitment to its M&A strategy aimed at expanding its therapeutic platform.
CAR T-cell therapy modifies a patient's own immune cells to provide a heightened ability to identify and eliminate cancer cells.
The target acquisition has developed a number of proprietary approaches to re-engineer CARs to better target solid tumors. The Company has generated pre-clinical proof of concept data that demonstrates the therapeutic potential of its lead CAR-T candidate for a range of solid tumors including colorectal, pancreatic, mesothelioma, ovarian and breast cancer
In addition, the target acquisition is also developing a novel, allogeneic CAR-T for the treatment of autoimmune diseases.
TC BioPharm Unveils Corporate Restructuring Plan; To Cut Up To 30% Of Workforce
U.S. Housing Starts Tumble More Than Expected In October
Eurozone Inflation Rises To 2% As Estimated
Bay Street Seen Opening Lower On Geopolitical Concerns; Canadian Inflation Data In Focus
Euro Slides Against Majors
FTSE 100 Slips As Geopolitics Weighs
European Stocks Tumble As Russia-Ukraine War Hurts Sentiment
